Jently Review
Best for: Shoppers wanting transparent compounded GLP-1 pricing plus NAD+, peptides, and metformin in one place
Jently is a clinician-guided telehealth service offering compounded GLP-1 weight management (semaglutide from $149/mo, tirzepatide from $199/mo) alongside NAD+, peptide therapy (sermorelin, glutathione), and metformin. Care is 100% online through licensed providers on the MD Integrations network. It runs on a monthly subscription and is operated by Jently, LLC, based in Brooklyn, New York.
No insurance needed · Vetted by our editors
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
Jently is a solid telehealth option with balanced features and pricing.
Jently at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide
- Starting price
- $149/mo ("As low as $149/mo" (homepage))
- FDA status
- No FDA warning letter on record
How we scored Jently
Each dimension is scored algorithmically from Jently’s real pricing, drugs offered, verification status, and disclosed inclusions — using the same six-dimension framework we apply to every provider.
Value25%
8.1/10At $149/mo, Jently runs about 12% below the $169 median for GLP-1 providers.
Effectiveness25%
8.3/10Jently offers both semaglutide and tirzepatide — the two GLP-1 molecules with the strongest published weight-loss trial outcomes.
User Experience15%
7.4/10Online intake and platform experience; 8 platform features disclosed.
Trust & Safety15%
7.2/10Core details confirmed by our editors; no FDA warning letters on file (last checked 2026-06-20).
Accessibility10%
6.3/10Jently's exact state footprint isn't published — confirm coverage in your state before signing up.
Support10%
6.1/10Jently provides standard clinician follow-up; no extended coaching or community program is disclosed.
How we verified this Jently review
Last checked 2026-06-20- Confirmed current pricing across 2 dose/plan tiers
- Checked the FDA warning-letter database for enforcement actions
- Walked the public intake/checkout flow on the provider's site
Pricing, availability, and compliance facts come from the provider's own site and primary regulatory records — see the sources below. Editorial confidence in this data: medium.
GLP-1 medications Jently offers
Tap any medication to read our plain-English guide — how it works, dosing, side effects, and what the trials found.
Pricing
"As low as $149/mo" (homepage)
"As low as $199/mo" (homepage)
Ready to get started?
Plans and promotions change often — check Jently's current pricing and active discounts before you decide.
What we like
- Compounded semaglutide from $149/mo and tirzepatide from $199/mo — pricing published
- Multi-pillar: GLP-1, NAD+, peptides (sermorelin, glutathione), and metformin
- 100% online with licensed providers via the MD Integrations network
- Subscription can be cancelled anytime through the patient portal
Watch-outs
- Specific pharmacy partner not named on the site
- No refunds once a consultation is completed or a prescription is dispensed
- Not LegitScript-certified (no certification displayed)
- States of operation not published
Is Jently worth it? Our verdict
Jently positions itself around one thing: Shoppers wanting transparent compounded GLP-1 pricing plus NAD+, peptides, and metformin in one place. It runs $149/month — toward the affordable end of the market.
How much Jently actually costs
- Compounded semaglutide — $149/month
- Compounded tirzepatide — $199/month
That puts Jently below the roughly $169 median ongoing price across the GLP-1 providers we track — a real cost advantage.
Medications: what Jently prescribes
Jently prescribes semaglutide (the active drug in Wegovy and Ozempic) and tirzepatide (the active drug in Zepbound and Mounjaro) — the two molecules with the strongest published weight-loss trial outcomes. These are dispensed as compounded formulations from a licensed pharmacy, which is how the price stays below brand-name pens. Compounded drugs aren't FDA-approved as finished products — the standard trade-off across the compounded-GLP-1 market.
Who Jently is best for — and who should skip it
A good fit if you…
- are focused on the lowest ongoing monthly cost.
Look elsewhere if you…
- specifically want an FDA-approved brand-name pen.
- need to bill insurance — like most of this market, it's cash-pay.
Trust, safety, and medical oversight
We found no FDA warning letters on file for the provider. As with any compounded program, the most important step you can take is confirming which licensed pharmacy fills your prescription and what's in the formulation — we explain how in our scoring methodology.
Bottom line
Jently earns its place on the shortlist mainly on price: at $149/month it's one of the more affordable ways to stay on a GLP-1, without obvious corners cut on access or oversight.
Ready to start with Jently?
Starting at $149/month. See current pricing and start your free consultation.
Alternatives to Jently
Editorial score · methodology
Enhance MD
Best for: lab-monitored compounded GLP-1 with mandatory video visit
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
The primary regulatory filings and peer-reviewed studies cited throughout this Jently review:
Sources & methodology — as of June 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
Ready to start with Jently?
Starting at $149/month. See current pricing and start your free consultation.